


*Table 1. Gelctin-3 level in the control and study group*

|                  | Study group (n = 25) |           | Control group (n = 20) |           | <i>U</i> | <i>Z</i> | <i>p</i> | <i>r</i> |
|------------------|----------------------|-----------|------------------------|-----------|----------|----------|----------|----------|
|                  | <i>M</i>             | <i>SD</i> | <i>M</i>               | <i>SD</i> |          |          |          |          |
| Galectin [ng/ml] | 13,45                | 11,63     | 7,29                   | 2,12      | 96,5     | -3,51    | <0,001   | 0,52     |




*Figure 1. Galectin-3 plasma concentration in the study and control group.*

*Table 2. Galectin-3 level in the control and study group after excluding patients with significant pathology of the circulatory system*

|                  | Study group (n = 23) |       | Control group (n = 20) |      | U   | Z    | p     |
|------------------|----------------------|-------|------------------------|------|-----|------|-------|
|                  | M                    | SD    | M                      | SD   |     |      |       |
| Galectin [ng/ml] | 12,69                | 11,12 | 7,29                   | 2,12 | 600 | 2,62 | 0,009 |

*Table 3. Galectin-3 level in the study group on patients with and without complex arrhythmia and in the study group.*

|                  | Without complex arrhythmia (n = 11) |      | Complex arrhythmia złożona (n = 14) |       | Control group (n = 20) |      | H     | p     |
|------------------|-------------------------------------|------|-------------------------------------|-------|------------------------|------|-------|-------|
|                  | M                                   | SD   | M                                   | SD    | M                      | SD   |       |       |
| Galectin [ng/ml] | 9,15                                | 2,30 | 16,83                               | 14,75 | 7,29                   | 2,12 | 14,84 | 0,001 |



*Figure 2. Galectin-3 level in the study group on patients with and without complex arrhythmia and in the study group.*

Table 4 Coordinates of *ROC curve*.

| Arrhythmia | Sensitivity | 1 - specificity |
|------------|-------------|-----------------|
| 19         | 1           | 1               |
| 35         | 1           | 0,86            |
| 75         | 1           | 0,79            |
| 101        | 0,91        | 0,64            |
| 151        | 0,82        | 0,64            |
| 350        | 0,82        | 0,57            |
| 1370       | 0,82        | 0,50            |
| 2620       | 0,73        | 0,50            |
| 3327       | 0,73        | 0,43            |
| 4799       | 0,73        | 0,36            |
| 6972       | 0,73        | 0,29            |
| 8150       | 0,64        | 0,29            |
| 8900       | 0,55        | 0,29            |
| 9512       | 0,55        | 0,21            |
| 12262      | 0,55        | 0,14            |
| 15795      | 0,46        | 0,14            |
| 16795      | 0,36        | 0,14            |
| 18195      | 0,27        | 0,14            |
| 22195      | 0,27        | 0,07            |
| 25150      | 0,18        | 0,07            |
| 26168,5    | 0,18        | 0               |
| 34210,5    | 0,09        | 0               |
| 41385      | 0           | 0               |

Table 5

*Galectin vs echo*

| Galectin-3 [ng/ml] |              |        |
|--------------------|--------------|--------|
| LVDD               | rho Spearman | 0,017  |
|                    | p            | 0,936  |
| Z                  | rho Spearman | 0,471  |
|                    | p            | 0,041  |
| EF                 | rho Spearman | -0,304 |
|                    | p            | 0,149  |
| PLAX               | rho Spearman | 0,132  |
|                    | p            | 0,547  |
| PLAX/m2            | rho Spearman | 0,168  |
|                    | p            | 0,456  |
| PSAX               | rho Spearman | 0,061  |
|                    | p            | 0,782  |
| PSAX m/2           | rho Spearman | 0,183  |
|                    | p            | 0,404  |

Table 6

*Galectin and CMR*

| Galectin-3 [ng/ml] |              |        |
|--------------------|--------------|--------|
| LV EF              | rho Spearman | -0,492 |
|                    | p            | 0,032  |
| LVES vol           | rho Spearman | -0,337 |
|                    | p            | 0,284  |
| LV EDvol           | rho Spearman | 0,091  |
|                    | p            | 0,729  |
| RVEF               | rho Spearman | -0,11  |
|                    | p            | 0,98   |
| RV ESvol           | rho Spearman | 0,242  |
|                    | p            | 0,473  |
| RV EDvol           | rho Spearman | 0,175  |
|                    | p            | 0,585  |

Table 7 Multiple linear regression analysis for the galectin-3 plasma concentration

|            | B      | SE    | $\beta$ | t     | p    |
|------------|--------|-------|---------|-------|------|
| (Constant) | 56.46  | 21.41 |         | 2.64  | .015 |
| arrhythmia | 0.0005 | .0001 | .49     | 2.88  | .009 |
| EF         | -0.68  | 0.30  | -.38    | -2.26 | .035 |